Neel Desai, MD
Ophthalmology · Largo, FLNPI 1609957786
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $606,449 of the $1,001,170 with a category attached, or 60.6%. 33 manufacturers reported payments, led by Biotissue Holdings Inc. at 39.8% of the total. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 815 payments — averaging $1228.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$399K
- Alcon$205K
- Sight Sciences, Inc.$89K
- Bausch & Lomb Americas Inc.$54K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$50K
- Sun Pharmaceutical Industries Inc.$36K
- plus $169K from 27 others
Across 20 payments — averaging $2983.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$38K
- Biotissue Holdings Inc.$13K
- Glaukos Corporation$5K
- Johnson & Johnson Surgical Vision, Inc.$4K
What the payments were for
- Consulting fees$606,44961%
- Speaking & faculty fees$322,96632%
- Travel & lodging$49,0275%
- Food & beverage$22,7272%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 160 | $398,744 |
| Alcon | 181 | $204,590 |
| Sight Sciences, Inc. | 74 | $89,106 |
| Bausch & Lomb Americas Inc. | 53 | $53,672 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 57 | $49,608 |
| Sun Pharmaceutical Industries Inc. | 50 | $36,316 |
| Kala Pharmaceuticals, Inc. | 44 | $27,577 |
| Dompe US, Inc. | 26 | $26,574 |
| Nordic Pharma, Inc. | 2 | $20,236 |
| Glaukos Corporation | 32 | $18,084 |
| Alcon Research LLC | 13 | $15,631 |
| Eyevance Pharmaceuticals LLC | 13 | $10,580 |
| Johnson & Johnson Surgical Vision, Inc. | 30 | $10,000 |
| Novartis | 14 | $9,598 |
| Shire North American Group Inc | 12 | $9,152 |
| Lumenis, Inc | 1 | $8,411 |
| AbbVie(2 entities) | 9 | $5,357 |
| Carl Zeiss Meditec, Inc. | 2 | $4,400 |
| Eyepoint US, Inc. | 3 | $1,356 |
| Omeros Corporation | 2 | $559 |
| Carl Zeiss Meditec USA, Inc. | 5 | $369 |
| Topcon Healthcare, Inc. | 4 | $290 |
| Amgen(2 entities) | 7 | $235 |
| Harrow Eye, LLC | 5 | $144 |
| NEW World Medical,inc. | 2 | $130 |
| Carl Zeiss Meditec Cataract Technology Inc. | 4 | $91 |
| Rxsight Inc | 2 | $89 |
| Lensar, Inc. | 1 | $64 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Coopervision Inc. | 1 | $54 |
| Oyster Point Pharma, Inc. | 2 | $41 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$202,865
- AmnioGraft$200,465
- AmnioGuard$150,059
- Clareon$90,507
- enVista MX60 IOL$60,575
- Crystalens Accommodating IOL (AT-52AO)$57,450
- Trulign IOL$57,450
- Hydrus Microstent$54,824
- Voyager DSLT$54,453
- TEARCARE SYSTEM$46,899
- STELLARIS ELITE$43,150
- Akreos AO IOL$41,250
- AcrySof IQ PanOptix UV IOL$40,441
- AcrySof IQ VIVITY$26,940
- Oxervate$25,840
- CRYSTALENS$25,117
- ENVISTA$23,117
- TRULIGN TORIC$23,117
- INVELTYS$21,712
- CEQUA$21,430
How this compares
$1,001,170 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 68 | $97,094 |
| XiidraLifitegrast | 34 | $32,524 |
| MieboPerfluorohexyloctane/Pf | 36 | $28,918 |
| Loteprednol Etabonate | 95 | $14,462 |
| Prednisolone Acetate | 246 | $14,045 |
| ProlensaBromfenac Sodium | 27 | $9,423 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $9,384 |
| LotemaxLoteprednol Etabonate | 14 | $5,078 |
| LumiganBimatoprost | 11 | $4,653 |
| FlarexFluorometholone Acetate | 23 | $3,564 |
| ValacyclovirValacyclovir Hcl | 63 | $3,468 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,413 |
| Ketorolac Tromethamine | 128 | $2,254 |
| Fluorometholone | 29 | $2,166 |
| Difluprednate | 15 | $1,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $5,357 | $111,13299 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $53,672 | $61,44270 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax | $49,608 | $28,963136 claims |
| Eyevance Pharmaceuticals LLCFlarex | $10,580 | $3,56423 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $20 | $41021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Largo
- Robert WeinstockLargo$605K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- William TrattlerMiami$579K
- Farrell TysonCape Coral$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.